Leaf411 Renews Appeal to Help Patients Across the Country Afford Medical Cannabis
In late 2022, Leaf411, a cannabis-trained nurse guidance service, announced that they resumed their affordability program for patients struggling to pay for their medicine. In a recent update, Leaf411 outlined their continued response to requests for assistance they are receiving from across the country.
According to a recent press release, Leaf411 sought to raise awareness about concerns they are hearing from patients across the country around the ability to afford medical cannabis. Last November, Leaf411 resumed their Affordability Program, which connects participating patients with free or low-cost donated cannabis products (1). Now the nation’s first no- or low-cost cannabis nurse guidance call service worries economic downturns in 2023 will increase the struggle for low-income patients to afford their medicine.
“Our recently relaunched Affordability Program has seen a huge increase in demand with 500 new applicants in the last 60 days and we are unable to meet many patient requests due to a lack of available products,” said Katherine Golden, CEO of Leaf411, in a press release (2). “We expect that demand for these services will continue to rise in 2023 as the economy struggles.”
According to the press release, costs of utilizing cannabis as medicine can include fees for obtaining a medical card and consultations with a cannabis clinician in addition to the cost of the medicine itself (2). Leaf411 says the fee for their scheduled guidance calls are a suggested $25 donation, and only 17% of callers are able to afford that (2).
“Unlike patients who benefit from insurance or other assistance programs to help pay for prescription pharmaceuticals, cannabis patients have almost no such resources—and those programs that exist are increasingly underfunded,” Golden continued (2). “The industry has spent a great deal of energy and time educating the public about cannabis medicine, but we are far behind in supporting the programs and services that support education and greater access. The economic challenges of the coming year will unfortunately expose just how vulnerable these patients are and why industry assistance programs need stronger support.”
Patients interested in participating in the Leaf411 Affordability Program can complete an application here.
Cannabis businesses interested in donating products to the program should contact Leaf411 at affordability@leaf411.org.
To learn more about the program, visit the Leaf411 website.
References
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Khan
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
German Medical Cannabis Market Has Yet to Reach Its Full Potential
December 25th 2024Germany’s Cannabis Act (CanG) is beginning to transform the country's medical cannabis market, with potential opportunities to expand telemedicine, improve physician training, and enhancing accessibility in this rapidly growing industry.
